Search hospitals > Quebec > MONTREAL
CHUM-Centre Hospitalier de l'Universite de Montreal
Claim this profileMONTREAL, Quebec H2X 3E4
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
466 reported clinical trials
98 medical researchers
Summary
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 558 conditions. There are 98 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Daniel Von Renteln, MDCentre Hospitalier de l'Université de Montréal (CHUM)1 year of reported clinical research
Studies Colorectal Cancer
Studies Colonic Polyps
12 reported clinical trials
17 drugs studied
Diane Provencher, MD, FRCSCCentre Hospitalier de l'Université de Montréal4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
12 reported clinical trials
20 drugs studied
Jean Raymond, MDCentre Hospitalier de l'Université de Montréal13 years of reported clinical research
Studies Aneurysm
Studies Brain Aneurysm
9 reported clinical trials
14 drugs studied
Moishe Liberman, MDCHUM2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
13 drugs studied
Clinical Trials running at CHUM-Centre Hospitalier de l'Universite de Montreal
Breast Cancer
Cancer
Prostate Cancer
Endometrial Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Squamous Cell Carcinoma
Melanoma
Glaucoma
Lung Cancer
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUM-Centre Hospitalier de l'Universite de Montreal?
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 558 conditions. There are 98 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.
Where is CHUM-Centre Hospitalier de l'Universite de Montreal located?
**Centre Hospitalier de l'Université de Montréal (CHUM)**
- **Location:** 1051 Sanguinet Street, Montreal, Quebec, Canada. Features underground city access to Champ-de-Mars metro station.
- **Type:** Public not-for-profit corporation.
- **Funding:** Supported by Quebec taxpayers via the Ministry of Health and Social Services.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at CHUM-Centre Hospitalier de l'Universite de Montreal:
- **Financial Support - CHUM**: For information about financial support, please consult the CHUM website.
- **Université de Montréal Contact**: Reach out at 514 343-6111 or mail to PO Box 6128, Centre-ville Station, Montréal, Quebec, H3C 3J7 for guidance or direction to the appropriate department.
- **Student Financial Assistance - Québec**: Contact the Student Financial Assistance office at the Ministry of Higher Education in Québec at their client services from Monday to Friday, 8:30 a.m. to 12:00 p.m. and 1:00 p.m. to 4:30 p.m., with extended hours on Wednesdays.
What insurance does CHUM-Centre Hospitalier de l'Universite de Montreal accept?
The Centre hospitalier de l'Université de Montréal (CHUM) is a public not-for-profit hospital funded mainly by Quebec taxpayers. CHUM accepts the Régie de l'assurance maladie du Québec (RAMQ) for Quebec residents, covering hospital care, physician services, and certain diagnostics. For those without RAMQ coverage, including international patients, CHUM provides private healthcare options and participates in international medical programs.
What awards or recognition has CHUM-Centre Hospitalier de l'Universite de Montreal received?
The CHUM Research Centre (CRCHUM) at the Centre Hospitalier de l'Universite de Montreal is renowned for its significant contributions to health research, as evidenced by its annual Research Awards of Excellence. It has also earned an "exceptional" rating in the 2020-2026 strategic plan by the Fonds de recherche du Québec — Santé, highlighting its outstanding performance in research activities.